BRPI0921777A2 - antagonistas da via hedgehog de piridazina tetrassubstituída - Google Patents
antagonistas da via hedgehog de piridazina tetrassubstituídaInfo
- Publication number
- BRPI0921777A2 BRPI0921777A2 BRPI0921777A BRPI0921777A BRPI0921777A2 BR PI0921777 A2 BRPI0921777 A2 BR PI0921777A2 BR PI0921777 A BRPI0921777 A BR PI0921777A BR PI0921777 A BRPI0921777 A BR PI0921777A BR PI0921777 A2 BRPI0921777 A2 BR PI0921777A2
- Authority
- BR
- Brazil
- Prior art keywords
- hedgehog pathway
- pathway antagonists
- tetrasubstituted
- tetrasubstituted pyridazine
- pyridazine hedgehog
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11536208P | 2008-11-17 | 2008-11-17 | |
PCT/US2009/063696 WO2010056620A1 (en) | 2008-11-17 | 2009-11-09 | Tetrasubstituted pyridazines hedgehog pathway antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0921777A2 true BRPI0921777A2 (pt) | 2016-01-12 |
Family
ID=41462228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921777A BRPI0921777A2 (pt) | 2008-11-17 | 2009-11-09 | antagonistas da via hedgehog de piridazina tetrassubstituída |
Country Status (12)
Country | Link |
---|---|
US (1) | US8445493B2 (pt) |
EP (1) | EP2358703B1 (pt) |
JP (1) | JP5518088B2 (pt) |
KR (1) | KR101335770B1 (pt) |
CN (1) | CN102216292B (pt) |
AU (1) | AU2009314288B2 (pt) |
BR (1) | BRPI0921777A2 (pt) |
CA (1) | CA2743264C (pt) |
EA (1) | EA018372B1 (pt) |
ES (1) | ES2446307T3 (pt) |
MX (1) | MX2011005176A (pt) |
WO (1) | WO2010056620A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0911618A2 (pt) | 2008-04-29 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de ftalazina dissubstituída. |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
PT2364185E (pt) | 2008-11-03 | 2013-07-24 | Lilly Co Eli | Ftalazina dissubstituída antagonista da via hedgehog |
CN102216285B (zh) | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
GB201309508D0 (en) | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
WO1997026258A1 (en) | 1996-01-15 | 1997-07-24 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
US6432970B2 (en) | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
IL138645A0 (en) | 1998-04-09 | 2001-10-31 | Univ Johns Hopkins Med | Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways |
AU780358B2 (en) | 1999-06-08 | 2005-03-17 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
ATE404200T1 (de) * | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES |
CN102964294A (zh) | 2004-09-02 | 2013-03-13 | 遗传技术研究公司 | Hedgehog信号转导的吡啶基抑制剂 |
EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
PE20090188A1 (es) * | 2007-03-15 | 2009-03-20 | Novartis Ag | Compuestos heterociclicos como moduladores de la senda de hedgehog |
WO2009002469A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
WO2009035568A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
BRPI0911618A2 (pt) | 2008-04-29 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de ftalazina dissubstituída. |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
PT2364185E (pt) | 2008-11-03 | 2013-07-24 | Lilly Co Eli | Ftalazina dissubstituída antagonista da via hedgehog |
CN102216285B (zh) | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2009
- 2009-11-09 MX MX2011005176A patent/MX2011005176A/es active IP Right Grant
- 2009-11-09 WO PCT/US2009/063696 patent/WO2010056620A1/en active Application Filing
- 2009-11-09 BR BRPI0921777A patent/BRPI0921777A2/pt not_active IP Right Cessation
- 2009-11-09 KR KR1020117011132A patent/KR101335770B1/ko not_active IP Right Cessation
- 2009-11-09 JP JP2011536403A patent/JP5518088B2/ja not_active Expired - Fee Related
- 2009-11-09 AU AU2009314288A patent/AU2009314288B2/en not_active Ceased
- 2009-11-09 EA EA201170700A patent/EA018372B1/ru not_active IP Right Cessation
- 2009-11-09 EP EP09752071.2A patent/EP2358703B1/en not_active Not-in-force
- 2009-11-09 CN CN200980145551.4A patent/CN102216292B/zh not_active Expired - Fee Related
- 2009-11-09 CA CA2743264A patent/CA2743264C/en not_active Expired - Fee Related
- 2009-11-09 US US13/122,225 patent/US8445493B2/en not_active Expired - Fee Related
- 2009-11-09 ES ES09752071.2T patent/ES2446307T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP2358703B1 (en) | 2013-12-25 |
EA201170700A1 (ru) | 2011-10-31 |
US8445493B2 (en) | 2013-05-21 |
JP5518088B2 (ja) | 2014-06-11 |
CA2743264C (en) | 2014-02-18 |
ES2446307T3 (es) | 2014-03-07 |
AU2009314288B2 (en) | 2013-05-02 |
EA018372B1 (ru) | 2013-07-30 |
KR101335770B1 (ko) | 2013-12-12 |
JP2012509265A (ja) | 2012-04-19 |
US20110178093A1 (en) | 2011-07-21 |
WO2010056620A1 (en) | 2010-05-20 |
CN102216292B (zh) | 2014-08-13 |
AU2009314288A1 (en) | 2010-05-20 |
MX2011005176A (es) | 2011-05-30 |
CN102216292A (zh) | 2011-10-12 |
CA2743264A1 (en) | 2010-05-20 |
KR20110075020A (ko) | 2011-07-05 |
EP2358703A1 (en) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921782A2 (pt) | antagonistas da via hedgehog de piridazina tetrassubstituída | |
BRPI1008749A2 (pt) | Derivados de benzodiazepina | |
BRPI0817601A2 (pt) | dispositivos de segurança | |
BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
BRPI0909656A2 (pt) | Microencapsulamento | |
BRPI0914743A2 (pt) | estrutura | |
BRPI0908116A2 (pt) | pulverizador | |
BRPI0911618A2 (pt) | antagonistas da via hedgehog de ftalazina dissubstituída. | |
BRPI0813843A2 (pt) | Contactor | |
BRPI0907952A2 (pt) | Combinação de vitamina d e 25-hidroxivitamina d3 | |
BRPI0913997A2 (pt) | isolamento de ciclopamina | |
ES1067502Y (es) | Columbario modular | |
BRPI0821498A2 (pt) | Estrutura de queimador | |
BRPI0921437A2 (pt) | antagonistas da via do hedgehog á base de fitalazina dissubstituída | |
BRPI0921777A2 (pt) | antagonistas da via hedgehog de piridazina tetrassubstituída | |
BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
BRPI0923550A2 (pt) | penico | |
BRPI0822013A2 (pt) | Estrutura de caldeira | |
FI20085899A0 (fi) | Puu-Metalli-komposiittirakenne | |
DK2323933T3 (da) | Stableenhed | |
DK2277578T3 (da) | Forstøver | |
FI20085651A0 (fi) | Palonsammutusjärjestelmä | |
DE112009001669A5 (de) | Sektionaltor | |
BRPI0921119A2 (pt) | quadro elétrico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |